6110 POSTER Combination Chemotherapy With Capecitabine (C), Irinotecan (I) Oxaliplatin (O) and Bevacizumab (B) (XELOXIRIA) as First Line Treatment of Metastatic Colorectal Cancer (MCRC) – Preliminary Results of a Phase l-ll Trial

Line Treatment ◽

First Line ◽

Preliminary Results ◽

Combination chemotherapy with capecitabine (C), irinotecan (I), oxaliplatin (O), and bevacizumab (B; XELOXIRIA) as first-line treatment of metastatic colorectal cancer (MCRC): Preliminary results of a phase I-II trial.

10.1200/jco.2011.29.15_suppl.e14073 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. e14073-e14073

Author(s):

S. Bazarbashi ◽

A. H. Aljubran ◽

H. Soudy ◽

A. Darwish ◽

A. Eltigani ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase I ◽

Line Treatment ◽

First Line ◽

Preliminary Results ◽

Oxaliplatin (L-OHP) combined with irinotecan (CPT-11), leucovorin (LV) and fluorouracil (5-FU) compared with irinotecan, leucovorin and fluorouracil as first-line treatment for metastatic colorectal cancer (MCC): Preliminary results of a multicenter randomized phase III trial

10.1200/jco.2004.22.90140.3532 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 3532-3532

Author(s):

J. Souglakos ◽

N. Ziras ◽

A. Polyzos ◽

A. Athanasiadis ◽

S. Kakolyris ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Iii ◽

Line Treatment ◽

First Line ◽

Phase Iii Trial ◽

Preliminary Results ◽

Preliminary results of a randomized phase III trial of the TTD Group comparing capecitabine and oxaliplatin (CapeOx) vs. oxaliplatin and 5-fluorouracil in continuous infusion (5-FU CI) as first line treatment in advanced or metastatic colorectal cancer (CRC)

10.1200/jco.2005.23.16_suppl.3524 ◽

2005 ◽

Vol 23 (16_suppl) ◽

pp. 3524-3524 ◽

Cited By ~ 7

Author(s):

J. Sastre ◽

B. Massuti ◽

J. M. Tabernero ◽

M. Chaves ◽

J. J. Reina ◽

...

Keyword(s):

Colorectal Cancer ◽

Continuous Infusion ◽

Phase Iii ◽

Line Treatment ◽

First Line ◽

Phase Iii Trial ◽

Preliminary Results ◽

A Phase III trial comparing either COntinuous chemotherapy plus cetuximab or INtermittent chemotherapy with standard continuous palliative combination chemotherapy with oxaliplatin and a fluoropyrimidine in first line treatment of metastatic colorectal cancer

http://isrctn.org/> ◽

10.1186/isrctn27286448 ◽

2012 ◽

Author(s):

Tim Maughan

Keyword(s):

Colorectal Cancer ◽

Phase Iii ◽

Line Treatment ◽

First Line ◽

Phase Iii Trial ◽

Intermittent Chemotherapy ◽

P-0239 Capecitabine and Oxaliplatin (XELOX) Combination Chemotherapy as First-Line Treatment for Metastatic Colorectal Cancer- A Phase II Study

Annals of Oncology ◽

10.1016/s0923-7534(20)30166-6 ◽

2012 ◽

Vol 23 ◽

pp. iv98

Author(s):

Hesham Tawfik ◽

HananGamal El-Deen

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Line Treatment ◽

First Line ◽

Oxaliplatin (L-OHP) combined with irinotecan (CPT-11), leucovorin (LV) and fluorouracil (5-FU) compared with irinotecan, leucovorin and fluorouracil as first-line treatment for metastatic colorectal cancer (MCC): Preliminary results of a multicenter randomized phase III trial

10.1200/jco.2004.22.14_suppl.3532 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 3532-3532 ◽

Cited By ~ 4

Author(s):

J. Souglakos ◽

N. Ziras ◽

A. Polyzos ◽

A. Athanasiadis ◽

S. Kakolyris ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Iii ◽

Line Treatment ◽

First Line ◽

Phase Iii Trial ◽

Preliminary Results ◽

Cetuximab and capecitabine as first-line treatment for elderly patients (pts) with metastatic colorectal cancer (mCRC): Preliminary results of TTD trial

10.1200/jco.2008.26.15_suppl.15027 ◽

2008 ◽

Vol 26 (15_suppl) ◽

pp. 15027-15027 ◽

Cited By ~ 5

Author(s):

C. Grávalos ◽

F. Rivera ◽

B. Massutí ◽

J. Sastre ◽

E. Marcuello ◽

...

Keyword(s):

Colorectal Cancer ◽

Elderly Patients ◽

Line Treatment ◽

First Line ◽

Preliminary Results ◽

Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) study (NRG- GI004/SWOG-S1610): A randomized phase III study of mFOLFOX6/bevacizumab combination chemotherapy with or without atezolizumab or atezolizumab monotherapy in the first-line treatment of patients with deficient DNA mismatch repair (dMMR) metastatic colorectal cancer.

10.1200/jco.2018.36.15_suppl.tps3615 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. TPS3615-TPS3615 ◽

Cited By ~ 3

Author(s):

James J. Lee ◽

Greg Yothers ◽

Samuel A. Jacobs ◽

Hanna Kelly Sanoff ◽

Deirdre Jill Cohen ◽

...

Keyword(s):

Colorectal Cancer ◽

Mismatch Repair ◽

Phase Iii ◽

Line Treatment ◽

First Line ◽

Dna Mismatch ◽

Phase Iii Study ◽

Faculty Opinions recommendation of A randomized, phase II trial of standard triweekly compared with dose-dense biweekly capecitabine plus oxaliplatin plus bevacizumab as first-line treatment for metastatic colorectal cancer: XELOX-A-DVS (dense versus standard).

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717697918.793457734 ◽

2012 ◽

Author(s):

Hans-Joachim Schmoll

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽

Dose Dense ◽

Faculty Opinions recommendation of FOLFOX4 plus cetuximab administered weekly or every second week in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer: a randomized phase II CECOG study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717997102.793478384 ◽

2013 ◽

Author(s):

Sabine Tejpar ◽

Loredana Vecchione

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Line Treatment ◽

Wild Type ◽

First Line ◽

Randomized Phase Ii ◽